Infinity Pharmaceuticals Inc. (Nasdaq: INFI) entered a global
collaboration with AbbVie Inc. (NYSE: ABBV) to develop and commercialize the
cancer treatment duvelisib. Shares of Infinity leaped $5.35 to $16.27 while AbbVie stock eased 15 cents to $54.92.
Infinity Pharmaceuticals collaborates with AbbVie
September 03, 2014 at 13:40 PM EDT
